Long-term Efficacy of Combination Therapy with Anti-arrhythmic Agents and Pravastatin in Patients with Paroxysmal Atrial Fibrillation

Journal of Arrhythmia

Volumn 23, Issue 2, 2007, Pages 124-130

  Komatsu, Takashi ^a   Tachibana, Hideaki ^a   Sato, Yoshihiro ^a   Ozawa, Mahito ^a   Ohshima, Kyoko ^a   Nakamura, Motoyuki ^a   Horiuchi, Daisuke ^b   Kobayashi, Takao ^b   Okumura, Ken ^b  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

Author keywords

Anti arrhythmic agents; Atrial fibrillation; Cholesterol lowering drugs; Prevention

Indexed keywords

EID: 85009571936     PISSN: 18804276     EISSN: 18832148     Source Type: Journal    
DOI: 10.4020/jhrs.23.124     Document Type: Article

References (25)

1. Ohsawa M, Okayama A, Sakata K, et al: Rapid increase in estimated number of persons with atrial fibrillation in Japan: an analysis from national surveys on cardiovascular disease in 1980, 1990 and 2000. J Epidemiol 2005; 15: 194-197
2. Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457
3. Stevenson WG, Stevenson LW: Atrial fibrillation in heart failure. N Engl J Med 1999; 341: 910-911
4. Frustaci A, Chimenti C, Bellocci F, et al: Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96: 1180-1184
5. Chung MK, Martin DO, Sprecher D, et al: C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886-2891
6. Dernellis J, Panaretou M: C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation. Acta Cardiol 2001; 56: 375-380
7. Young-Xu Y, Jabbour S, Goldberg R, et al: Usefulness of statin agents in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003; 92: 1379-1383
8. Siu CW, Lau CP, Tse HF: Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003; 92: 1343-1345
9. Fuster V, Ryden LE, Asinger RW, et al: ACC/AHA/ ESC guidelines for the management of patients with atrial fibrillation: executive summary of a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation 2001; 104: 2118-2150
10. World Health Organization, International Society of Hypertension Writing Group: 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1011-1053
11. Investigating Committee of Guideline for Diagnosis and Treatment of Hyperlipidemias: Guidelines for diagnosis and treatment of hyperlipidemia in adults. J Jpn Atheroscler Soc 1997; 25: 1-34
12. Komatsu T, Sato Y, Tachibana H, et al: Randomized crossover study of the long-term effects of pilsicainide and cibenzoline in preventing recurrence of symptomatic paroxysmal atrial fibrillation. Circ J 2006; 70: 667-672
13. Basso C, Corrado D, Rossi L, et al: Ventricular preexcitation in children and young adults: atrial myocarditis as a possible trigger of sudden death. Circulation 2001; 103: 269-275
14. Fromer M, Genton C, Schlapper J, et al: Is there an isolated arrhythmogenic right atrial myopathy? Eur Heart J 1990; 11: 566-571
15. Kumagai K, Nakashima H, Saku K: The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004; 62: 105-111
16. Ridker PM, Rifai N, Stampfer MJ, et al: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-1772
17. Ridker PM, Buring JE, Shih J, et al: Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-733
18. Cemak J, Key NS, Bach RR, et al: C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513-520
19. Pound EM, Kang JX, Leaf A: Partitioning of polyunsa-turated fatty acids, which prevent cardiac arrhythmia, into phospholipids cell membranes. J Lipid Res 2001; 42: 346-351
20. Lamers JM, Hartog JM, Verdouw PD, et al: Dietary fatty acids and myocardial function. Basic Res Cardiol 1987; 82: 209-221
21. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-988
22. Ridker PM, Rifai N, Pfeffer MA, et al: Long-term effects of pravastatin on plasma concentration of C-reactive protein: the Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230-235
23. Mitchell LB, Powell JL, Gillis AM, et al: Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. J Am Coll Cardiol 2003; 42: 81-87
24. Allessie MA: Atrial electrophysiologic remodling. J Cardiovasc Electrophysiol 1998; 9: 1378-1393
25. Lefer AM, Scalia R, Lefer DJ: Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res 2001; 49: 281-287